Recursion Pharmaceuticals (NASDAQ:RXRX) Insider Najat Khan Sells 124,403 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) insider Najat Khan sold 124,403 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $4.41, for a total transaction of $548,617.23. Following the sale, the insider owned 611,135 shares in the company, valued at approximately $2,695,105.35. This trade represents a 16.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Recursion Pharmaceuticals Trading Down 2.8%

Shares of RXRX opened at $4.13 on Tuesday. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $3.79 and a fifty-two week high of $12.36. The company has a market capitalization of $2.15 billion, a PE ratio of -2.29 and a beta of 0.94. The stock has a fifty day moving average of $4.73 and a two-hundred day moving average of $5.10. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.60 and a current ratio of 4.60.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.02. The business had revenue of $5.18 million for the quarter, compared to analysts’ expectations of $19.36 million. Recursion Pharmaceuticals had a negative return on equity of 72.74% and a negative net margin of 1,637.81%.The business’s revenue was down 80.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.34) earnings per share. As a group, analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Institutional Trading of Recursion Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Brighton Jones LLC raised its position in Recursion Pharmaceuticals by 49.4% in the fourth quarter. Brighton Jones LLC now owns 20,261 shares of the company’s stock valued at $137,000 after purchasing an additional 6,699 shares during the period. Invesco Ltd. grew its stake in shares of Recursion Pharmaceuticals by 13.4% in the first quarter. Invesco Ltd. now owns 202,531 shares of the company’s stock valued at $1,071,000 after buying an additional 23,912 shares in the last quarter. AlphaQuest LLC purchased a new stake in shares of Recursion Pharmaceuticals during the 1st quarter valued at about $36,000. Ieq Capital LLC lifted its position in Recursion Pharmaceuticals by 56.3% during the 1st quarter. Ieq Capital LLC now owns 53,228 shares of the company’s stock worth $282,000 after acquiring an additional 19,180 shares in the last quarter. Finally, Royal Bank of Canada boosted its holdings in Recursion Pharmaceuticals by 627.6% in the 1st quarter. Royal Bank of Canada now owns 269,013 shares of the company’s stock worth $1,423,000 after acquiring an additional 232,038 shares during the period. 89.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. raised shares of Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $10.00 to $11.00 in a research report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Wednesday, October 8th. Morgan Stanley set a $11.00 price objective on Recursion Pharmaceuticals in a report on Wednesday, December 17th. UBS Group set a $11.00 target price on Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Finally, Needham & Company LLC reissued a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, September 11th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Recursion Pharmaceuticals presently has an average rating of “Hold” and an average price target of $9.50.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.